Pulmonx Corporation (LUNG) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Pulmonx Corporation (LUNG) Healthcare & Pipeline Overview

Pulmonx Corporation is a leader in the development of minimally invasive devices for chronic obstructive pulmonary diseases, offering innovative solutions like the Zephyr Endobronchial Valve and Chartis Pulmonary Assessment System to improve patient outcomes in emphysema treatment.

What Is the Investment Thesis for LUNG?

The Zephyr Endobronchial Valve has shown promising clinical outcomes, with studies indicating significant improvements in lung function and quality of life for patients suffering from severe emphysema. The global market for COPD treatments is projected to grow significantly, with an estimated CAGR of 4.5% through 2028, driven by an aging population and increasing prevalence of respiratory diseases. Pulmonx's gross margin of 75.5% indicates strong operational efficiency, while the company's focus on expanding its international footprint presents additional growth opportunities. However, the ongoing negative profit margin of -60.1% highlights the need for continued investment in R&D and market expansion to achieve profitability. As Pulmonx continues to innovate and capture market share, its strategic initiatives and product pipeline could drive revenue growth and enhance shareholder value.

Based on FMP financials and quantitative analysis

LUNG Key Highlights

Market Cap of $78.8M reflects the company's current valuation in the medical device sector.

• Gross margin of 75.5% indicates strong profitability potential compared to industry averages.
• Negative profit margin of -60.1% highlights ongoing investment needs for growth and development.
• Beta of 0.19 suggests lower volatility compared to the broader market, appealing to risk-averse investors.
• No dividend yield as the company reinvests earnings into R&D and expansion efforts.

Who Are LUNG's Competitors?

LUNG is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are LUNG's Key Strengths?

Innovative product offerings with proven clinical outcomes.

• Strong gross margin indicating operational efficiency.
• Established brand recognition in the pulmonary device market.
• Diverse geographic reach enhancing market opportunities.

What Are LUNG's Weaknesses?

Negative profit margin indicating ongoing financial challenges.

• Dependence on a limited number of key products for revenue.
• Relatively small market cap compared to larger competitors.
• Need for continuous investment in R&D to maintain competitive advantage.

What Could Drive LUNG Stock Higher?

Expansion of the Zephyr Endobronchial Valve into new international markets expected in Q3 2026.

• Continued clinical trials for the StratX Lung Analysis Platform to enhance product capabilities.
• Engagement with healthcare providers to increase adoption rates of Pulmonx products.
• Anticipated regulatory approvals for new product variations in the EU by late 2026.
• Investment in R&D to innovate and improve existing product offerings.

What Are the Key Risks for LUNG?

Financial-distress signal — its Altman Z-Score of -5.78 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-92.9%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Regulatory hurdles that could delay product launches in new markets.
• Competition from larger medical device companies with more resources.
• Market fluctuations that may impact healthcare spending and investment in new technologies.
• Dependence on a limited product portfolio which may affect revenue stability.

What Are the Growth Opportunities for LUNG?

• Expansion into Emerging Markets: Pulmonx has significant growth opportunities in emerging markets, where the prevalence of COPD is rising due to urbanization and pollution. The Asia-Pacific region, in particular, is projected to grow at a CAGR of 5.2% through 2028, driven by increasing healthcare access and awareness. By establishing partnerships and distribution channels in these regions, Pulmonx can enhance its market presence and drive sales.
• Product Line Extensions: The potential to expand Pulmonx's product portfolio with complementary devices and therapies presents a strategic growth avenue. Developing additional products that enhance the efficacy of the Zephyr Valve or address other aspects of COPD treatment could capture a larger share of the market. The global market for COPD-related devices is expected to grow significantly, providing a fertile ground for new product introductions.
• Technological Advancements: Continued investment in R&D to enhance existing products and develop novel solutions can drive growth. Innovations in the StratX Lung Analysis Platform, such as AI-driven analytics, could improve clinical decision-making and patient outcomes. The integration of advanced technologies into Pulmonx's offerings will differentiate its products in a competitive landscape, potentially leading to increased adoption.
• Regulatory Approvals: Securing additional regulatory approvals for the Zephyr Valve in new markets can catalyze growth. As healthcare regulations evolve, gaining timely approvals can provide a competitive edge and open new revenue streams. Pulmonx's proactive approach to regulatory engagement will be crucial in capitalizing on these opportunities.
• Strategic Partnerships: Collaborating with healthcare providers and research institutions can enhance Pulmonx's credibility and market reach. Strategic partnerships may facilitate clinical trials, improve product visibility, and foster innovation. By aligning with key stakeholders in the healthcare ecosystem, Pulmonx can leverage shared resources and expertise to accelerate growth.

What Threats Does LUNG Face?

• Intense competition from established medical device companies.
• Regulatory challenges that may impact product approvals.
• Market volatility affecting healthcare spending and investment.
• Potential for technological advancements from competitors to outpace Pulmonx.

What Are LUNG's Competitive Advantages?

• Strong intellectual property portfolio protecting innovative technologies.
• Proven clinical efficacy of products, enhancing trust and adoption among healthcare providers.
• Established relationships with key opinion leaders in the pulmonary medicine field.
• Focus on minimally invasive procedures, aligning with industry trends towards less invasive treatments.
• Comprehensive data analytics capabilities through the StratX platform, providing a competitive edge.

What Does LUNG Do?

Founded in 1995 and headquartered in Redwood City, California, Pulmonx Corporation is a pioneering medical technology company dedicated to transforming the treatment landscape for chronic obstructive pulmonary diseases (COPD). Initially established as Pulmonx, the company rebranded to Pulmonx Corporation in December 2013 to better reflect its innovative approach and expanding product offerings. Pulmonx specializes in minimally invasive devices designed to address severe emphysema, a debilitating condition affecting millions globally. Its flagship product, the Zephyr Endobronchial Valve, is a groundbreaking solution that targets hyperinflation in adult patients, significantly improving lung function and quality of life. In addition to the Zephyr Valve, Pulmonx offers the Chartis Pulmonary Assessment System, a sophisticated balloon catheter and console system equipped with flow and pressure sensors, which assesses collateral ventilation, an essential factor in determining treatment efficacy. The company further enhances its service offering through the StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis tool that provides critical insights on emphysema destruction and lobar volume, aiding clinicians in identifying optimal treatment targets. Pulmonx serves a diverse patient base across the United States, Europe, the Middle East, Africa, and the Asia-Pacific region, positioning itself as a key player in the global market for advanced pulmonary therapies. With a commitment to innovation and patient care, Pulmonx Corporation continues to expand its presence and impact in the healthcare sector.

What Products and Services Does LUNG Offer?

• Develop minimally invasive medical devices for chronic obstructive pulmonary diseases.
• Offer the Zephyr Endobronchial Valve for treating severe emphysema.
• Provide the Chartis Pulmonary Assessment System to assess collateral ventilation.
• Deliver the StratX Lung Analysis Platform for quantitative analysis of lung conditions.
• Serve patients across the United States, Europe, the Middle East, Africa, and Asia-Pacific.
• Focus on innovative solutions to improve patient outcomes in pulmonary health.

How Does LUNG Make Money?

• Generate revenue through the sale of medical devices and related services.
• Leverage proprietary technology in the development of advanced pulmonary therapies.
• Engage in partnerships with healthcare providers for product distribution and clinical trials.
• Utilize a direct sales model to reach hospitals and clinics effectively.
• Invest in R&D to continually innovate and expand the product portfolio.

What Industry Does LUNG Operate In?

The medical devices industry is experiencing robust growth, driven by technological advancements and an increasing focus on minimally invasive procedures. The global market for COPD treatments is expected to reach $20 billion by 2028, with a significant portion attributed to innovative devices like those offered by Pulmonx. The competitive landscape includes established players and emerging startups, all vying for market share in a sector characterized by rapid innovation and evolving patient needs. Pulmonx's unique product offerings position it favorably within this dynamic environment, as healthcare providers seek effective solutions for chronic respiratory conditions.

Who Are LUNG's Key Customers?

• Healthcare providers including hospitals and specialty clinics.
• Patients suffering from chronic obstructive pulmonary diseases, particularly emphysema.
• Pulmonologists and respiratory specialists seeking advanced treatment options.
• Healthcare systems in the United States and international markets.
• Research institutions conducting studies on pulmonary health.

Over the past six months, Pulmonx Corporation insiders filed 20 SEC Form 4 transactions — 14 sales and 6 purchases. On net that is roughly 162K shares acquired (about $177K) — insiders putting money in tends to read as conviction.

Pulmonx Corporation has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 14.5% above estimates on average.

Pulmonx Corporation's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.78 places it in the distress zone, a signal of elevated financial risk.

Return on equity for Pulmonx Corporation stands at -92.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -44.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -48.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.91 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -88.2%, the inverse of the P/E and a quick read on earnings relative to price.

Pulmonx Corporation (LUNG) Valuation Context

Valued at $78.8M, LUNG is classified as a micro-cap stock. Analyst price targets span from $2.50 to $20.00, with a consensus of $10.00. At the current price of $1.86, that implies approximately 436% upside potential. Relative to its peer group, LUNG's quantitative score of 21/100 is below the peer average of 60/100.

LUNG Revenue & Earnings Trend

In Q2 FY2026, LUNG generated $22.8M in top-line revenue, marking a sequential increase of 10.5%. The company recorded a net loss of $10.1M, with diluted EPS of $-0.24. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, LUNG averaged $-0.29 in diluted EPS.

Company Profile

Pulmonx Corporation operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Redwood City, US. The company is led by CEO Glendon E. French. LUNG has traded publicly since 2020.

LUNG Financials

LUNG Latest News

LUNG Analyst Consensus

LUNG MoonshotScore

LUNG Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources